ArticleWorld journal of urology2026
Evaluating learning curves and robotic skill transfer to hinotori™: CUSUM analysis after complete platform conversion in radical prostatectomy.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Feasibility and perioperative outcomes of Senhance-assisted robotic cholecystectomy: a single-arm meta-analysis.Journal of robotic surgery · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION &
objectiveThe transference of surgical skills from da Vinci® to hinotori™ robotic surgery system remain limited in the context of radical prostatectomy. The aim of our study was to evaluate the learning curves and operative outcomes of hinotori™ robot-assisted radical prostatectomy (RARP) by experienced transitioning surgeons.
methodsA retrospective study of the initial consecutive hinotori™ RARP cases at a high-volume robotic centre was conducted. All transitioning surgeons included in the study stopped using da Vinici entirely. The cumulative sum (CUSUM) analysis was performed on console time at both institutional and surgeon levels. Console time was defined exclusively as active robotic operating time, measured from console engagement (surgeon seated) to console disengagement (surgeon standing), and did not include docking or skin-to-skin time. Collected perioperative variables encompassed patient characteristics, surgical parameters, and postoperative outcomes. The follow-up period was 3 months.
resultsThe first 100 consecutive hinotori™ RARPs within a single institution were included. Proficiency discerned by CUSUM analysis was achieved after 45 cases at the institutional level. Among 4 transitioning surgeons, proficiency was achieved after 11, 11, 11 and 9 cases respectively. Institutional median total operative time decreased from 245 (IQR 223− 68) to 220 (IQR 186.5–262.5) minutes (p = 0.019), and median console time decreased from 205 (IQR 188–232) to 185 (IQR 155.5–231) minutes (p = 0.032) after reaching proficiency. No differences were observed in estimated blood loss (EBL), continence rate at 3-month follow-up (82% vs. 84%, p = 0.494), or biochemical recurrence-free survival (96% vs. 100%, p = 0.951). No Clavien–Dindo ≥ Grade III complications occurred in either proficiency or learning phases. Positive surgical margin (PSM) rates (7 (15.6%) vs. 1 (1.8%), p = 0.021) decreased after institutional proficiency was achieved.
conclusionSurgeons with prior da Vinci® experience rapidly and consistently transferred their robotic skills to the hinotori™ platform. Complication rates remained stable during the learning curve and once proficiency was reached, positive surgical margins rates notably decreased.
Indexed as
Identifiers
41880020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.